ES2176106A1 - Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral. - Google Patents

Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.

Info

Publication number
ES2176106A1
ES2176106A1 ES200003018A ES200003018A ES2176106A1 ES 2176106 A1 ES2176106 A1 ES 2176106A1 ES 200003018 A ES200003018 A ES 200003018A ES 200003018 A ES200003018 A ES 200003018A ES 2176106 A1 ES2176106 A1 ES 2176106A1
Authority
ES
Spain
Prior art keywords
trimetazidine
oral administration
sustained release
matrix tablet
prolonged release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200003018A
Other languages
English (en)
Other versions
ES2176106B1 (es
Inventor
De Barochez Bruno Huet
Claude Dauphant
Patrick Wuthrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9553398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2176106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of ES2176106A1 publication Critical patent/ES2176106A1/es
Application granted granted Critical
Publication of ES2176106B1 publication Critical patent/ES2176106B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral. La presente invención tiene por objeto un comprimido matricial que permite la liberación prolongada de trimetazidina o de una de sus sales de adición de un ácido farmacéuticamente aceptable después de la administración por vía oral, caracterizada porque la liberación prolongada está controlada por la utilización de un polímero derivado de celulosa.
ES200003018A 1999-12-17 2000-12-15 Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral. Expired - Fee Related ES2176106B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915960A FR2802424B1 (fr) 1999-12-17 1999-12-17 Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale

Publications (2)

Publication Number Publication Date
ES2176106A1 true ES2176106A1 (es) 2002-11-16
ES2176106B1 ES2176106B1 (es) 2004-01-16

Family

ID=9553398

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200003018A Expired - Fee Related ES2176106B1 (es) 1999-12-17 2000-12-15 Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
ES00403533.3T Expired - Lifetime ES2240033T5 (es) 1999-12-17 2000-12-15 Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00403533.3T Expired - Lifetime ES2240033T5 (es) 1999-12-17 2000-12-15 Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral

Country Status (33)

Country Link
EP (1) EP1108424B2 (es)
JP (2) JP2001172181A (es)
KR (1) KR100456933B1 (es)
CN (1) CN1166408C (es)
AR (1) AR026968A1 (es)
AT (1) ATE296622T1 (es)
AU (1) AU780011B2 (es)
BG (1) BG65773B1 (es)
BR (1) BR0005915A (es)
CY (1) CY2347B1 (es)
CZ (1) CZ299461B6 (es)
DE (1) DE60020501T3 (es)
DK (1) DK1108424T4 (es)
EA (2) EA200501901A1 (es)
ES (2) ES2176106B1 (es)
FR (1) FR2802424B1 (es)
GE (1) GEP20053540B (es)
GR (1) GR1003658B (es)
HK (1) HK1036937A1 (es)
HU (1) HU226956B1 (es)
IE (1) IE20001017A1 (es)
IT (1) IT1317075B1 (es)
LU (1) LU90700B1 (es)
MX (1) MXPA00012462A (es)
NZ (1) NZ508912A (es)
OA (1) OA12121A (es)
PL (1) PL206994B1 (es)
PT (2) PT1108424E (es)
SI (1) SI1108424T2 (es)
SK (1) SK286752B6 (es)
UA (1) UA80087C2 (es)
WO (1) WO2001043747A1 (es)
ZA (1) ZA200007548B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1195160E (pt) * 2000-10-05 2009-12-07 Usv Ltd Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
JP4884772B2 (ja) * 2003-08-04 2012-02-29 杏林製薬株式会社 経口徐放性錠剤
SG126792A1 (en) * 2005-04-27 2006-11-29 Servier Lab Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation
CZ300307B6 (cs) * 2006-01-04 2009-04-15 Zentiva, A. S. Tableta s obsahem trimetazidinu nebo jeho farmakologicky akceptovatelné soli s modifikovaným uvolnováním
EA009776B1 (ru) * 2006-07-18 2008-04-28 Мераб Ревазович Кокеладзе Способ изготовления таблетированной лекарственной формы триметазидина дигидрохлорида и ее состав
EA009810B1 (ru) * 2006-12-26 2008-04-28 Закрытое Акционерное Общество "Канонфарма Продакшн" Матрица для изготовления таблетированной лекарственной формы и способ лечения
WO2009034541A2 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
US20110300209A1 (en) 2009-01-20 2011-12-08 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
WO2010086868A1 (en) * 2009-01-30 2010-08-05 Lupin Limited Pharmaceutical compositions of trimetazidine
TR201001902A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
RU2445958C2 (ru) * 2010-04-20 2012-03-27 Общество с ограниченной ответственностью "Озон" (ООО "Озон") Матричная таблетка с основой для пролонгированного высвобождения триметазидина и способ ее изготовления
US20110274751A1 (en) 2010-05-04 2011-11-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Trimetazidine formulation with different release profiles
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
FR2986431B1 (fr) 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CN102824644B (zh) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 使用羟丙基纤维素制备的高稳定性的缓释片
KR20160118733A (ko) 2015-04-03 2016-10-12 이인현 호스 권취용 호스 안내장치 및 이를 구비한 호스 권취기
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963A1 (fr) * 1980-09-30 1982-04-02 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPS61212517A (ja) * 1985-03-18 1986-09-20 Nippon Chemiphar Co Ltd 持続性錠剤
EP0673649A1 (fr) * 1994-03-24 1995-09-27 Adir Et Compagnie Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale
ES2083119T3 (es) * 1991-06-18 1996-04-01 Adir Comprimido matricial que permite la liberacion prolongada de indapamida despues de su administracion por via oral.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
KR850006132A (ko) * 1984-02-29 1985-10-02 진 크라메르, 한스 루돌프 하우스 브로모크립틴 조성물
JPS61293931A (ja) * 1985-06-24 1986-12-24 Teijin Ltd 徐放性医薬品組成物
EP0207638B1 (en) † 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
FR2681324B1 (fr) * 1991-09-18 1993-10-29 Adir Cie Nouveaux derives de la trimetazidine, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR940021051A (ko) * 1993-03-03 1994-10-17 손정삼 3단계 약물방출형 지속성 정제
RU2082400C1 (ru) * 1993-12-16 1997-06-27 Акционерное общество - Фармацевтическая фирма "Ник-Фарм" Способ получения нитроглицерина пролонгированного действия

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963A1 (fr) * 1980-09-30 1982-04-02 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPS61212517A (ja) * 1985-03-18 1986-09-20 Nippon Chemiphar Co Ltd 持続性錠剤
ES2083119T3 (es) * 1991-06-18 1996-04-01 Adir Comprimido matricial que permite la liberacion prolongada de indapamida despues de su administracion por via oral.
EP0673649A1 (fr) * 1994-03-24 1995-09-27 Adir Et Compagnie Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale

Also Published As

Publication number Publication date
JP2001172181A (ja) 2001-06-26
BG106927A (en) 2003-05-30
ITRM20000667A1 (it) 2002-06-14
EA200501901A1 (ru) 2006-06-30
WO2001043747A1 (fr) 2001-06-21
DE60020501D1 (de) 2005-07-07
IT1317075B1 (it) 2003-05-26
HUP0004966A3 (en) 2008-04-28
CZ299461B6 (cs) 2008-08-06
GR1003658B (el) 2001-09-05
DK1108424T4 (da) 2013-12-16
BR0005915A (pt) 2001-10-02
SK286752B6 (sk) 2009-04-06
ES2176106B1 (es) 2004-01-16
EA200001201A3 (ru) 2001-10-22
OA12121A (en) 2003-10-20
HU0004966D0 (es) 2001-02-28
ATE296622T1 (de) 2005-06-15
HK1036937A1 (en) 2002-01-25
UA80087C2 (en) 2007-08-27
KR100456933B1 (ko) 2004-11-10
EA008223B1 (ru) 2007-04-27
SK8632002A3 (en) 2002-10-08
NZ508912A (en) 2002-04-26
AU780011B2 (en) 2005-02-24
CY2347B1 (en) 2004-06-04
MXPA00012462A (es) 2002-06-04
GEP20053540B (en) 2005-06-10
EP1108424B1 (fr) 2005-06-01
HUP0004966A2 (en) 2002-06-29
HU226956B1 (en) 2010-03-29
PT102542A (pt) 2001-06-29
DE60020501T2 (de) 2006-04-27
PL206994B1 (pl) 2010-10-29
CZ20022082A3 (cs) 2002-09-11
EP1108424A1 (fr) 2001-06-20
EP1108424B2 (fr) 2013-09-04
PT1108424E (pt) 2005-08-31
JP2007314578A (ja) 2007-12-06
IE20001017A1 (en) 2002-04-03
ES2240033T5 (es) 2014-01-16
SI1108424T1 (en) 2005-10-31
ZA200007548B (en) 2001-06-19
ES2240033T3 (es) 2005-10-16
DE60020501T3 (de) 2014-03-20
EA200001201A2 (ru) 2001-08-27
DK1108424T3 (da) 2005-10-03
FR2802424B1 (fr) 2002-02-15
PL344564A1 (en) 2001-06-18
ITRM20000667A0 (it) 2000-12-14
LU90700B1 (fr) 2007-12-03
WO2001043747A8 (fr) 2001-09-07
FR2802424A1 (fr) 2001-06-22
BG65773B1 (bg) 2009-11-30
AR026968A1 (es) 2003-03-05
SI1108424T2 (sl) 2014-02-28
CN1302663A (zh) 2001-07-11
KR20010062478A (ko) 2001-07-07
AU7228500A (en) 2001-06-21
CN1166408C (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
BG105857A (en) Pregelatinized starch in a controlled release formulation
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
CY2460B1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors.
WO2004082615A3 (en) A process for preparing sustained release tablets
EP0966966A3 (en) Nefazodone dosage form
AP2003002763A0 (en) Controlled release formulations for oral administration
DE69716586D1 (de) Gepufferte orthoesterpolymere enthaltende arzneimittel
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
GR3018685T3 (en) Method for the manufacture of a controlled release solid unit dosage form.
IL143985A0 (en) New use of melagatran
WO2000054780A3 (en) Corticosteroid formulation
TNSN06003A1 (en) Saquinavir mesylate oral dosage form
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
HUP9903410A2 (hu) Tolfenámsavat vagy gyógyszerészetileg elfogadható sóját tartalmazó, gyors hatóanyag-leadású tabletta
NZ523606A (en) Pharmaceutical compositions and methods for use
HK1041000A1 (en) Novel pyrimidine derivatives and processes for thepreparation thereof.
CA2285852A1 (en) Pharmaceutical tablet comprising lisinopril disodium and microcrystalline cellulose
HU0100122D0 (en) Use of tiludronic acid and derivatives thereof in poultry for preparation of a medicinal product for preventing and treating osteoporosis
BG106428A (en) Pharmaceutical compositions for treating psoriasis
WO2000046193A3 (en) Ether derivatives having neuronal activity

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20021116

Kind code of ref document: A1

Effective date: 20021116

FG2A Definitive protection

Ref document number: 2176106B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807